UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Apr

    13

    UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting

    Read More

    Apr

    01

    UCB’s Catherine Rives and Alexandria Harrold Recognized by Healthcare Businesswomen’s Association (HBA) as Luminary and Rising Star

    Read More

    Mar

    27

    Evolving Expectations in Immunologic Disease: Our work with those living with immune-mediated diseases and HCPs

    Read More

    Mar

    27

    UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

    Read More

    Mar

    27

    UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa

    Read More

    Mar

    24

    UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs

    Read More

    Mar

    16

    3 in 3: Advancing hope for rare and ultra-rare disease communities, one innovation at a time

    Read More

    Mar

    11

    BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50

    Read More

    Mar

    10

    Innovation Equals Access: How UCB Delivered for Patients in 2025

    Read More

    Feb

    04

    More than Medicine: UCB's Holistic Approach to Supporting MG Patients

    Read More